Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 2, 2001, Pages 191-193

  Hansel A ^a   Bucher, H C ^a   Nuesch R ^a   Battegay, M ^a  

^a KANTONSSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

EID: 0035251551     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200102010-00016     Document Type: Letter

References (8)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
3. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice
4. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy HAART) regimen in a cohort of antiretroviral naive patients
5. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
6. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
7. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
8. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults